Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Planchard

Showing results (31-40 of 243) with videos related to

Pageof 25
Sort By:
Bulletin Du Cancer|November 6, 2007
[Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives]Antoine Italiano, Benjamin Besse, David Planchard, et al.
Therapeutic Advances in Respiratory Disease|November 6, 2019
Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experienceAngela Botticella, Laura Mezquita, Cecile Le Pechoux, et al.
Lung Cancer (Amsterdam, Netherlands)|December 23, 2021
Antibody-drug conjugates: A promising novel therapeutic approach in lung cancerAakash Desai, Pamela Abdayem, Alex A Adjei, et al.
Bulletin Du Cancer|April 5, 2011
[DNA repair pathways and non-small cell lung cancer: clinical perspectives]Ken André Olaussen, David Planchard, Julien Adam, et al.
Seminars in Oncology|December 10, 2009
Differential expression of biomarkers in men and womenDavid Planchard, Yohann Loriot, Aicha Goubar, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 23, 2015
A Long-Term Spinal Intramedullary Response to Ceritinib in ALK Rearranged Non-Small-Cell Lung CancerJosette Biya, Caroline Caramella, Colin R Lindsay, et al.
Critical Reviews in Oncology/Hematology|May 5, 2025
Evolving treatment for advanced non-small cell lung cancer harbouring common EGFR activating mutationsIgor Gomez-Randulfe, Federico Monaca, David Planchard, et al.
Bulletin Du Cancer|March 31, 2015
[Second generation ALK inhibitors in non-small cell lung cancer: systemic review]Marie Viala, Solenn Brosseau, David Planchard, et al.
Cancer|March 15, 2012
p38 Mitogen-activated protein kinase signaling, ERCC1 expression, and viability of lung cancer cells from never or light smoker patientsDavid Planchard, Valérie Camara-Clayette, Nicolas Dorvault, et al.
Future Oncology (London, England)|June 30, 2021
Biosimilars in an era of rising oncology treatment optionsMarc Peeters, David Planchard, Mark Pegram, et al.
Pageof 25

Showing results (31-40 of 243) with videos related to

Sort By:
Pageof 25
Bulletin Du Cancer|November 6, 2007
[Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives]Antoine Italiano, Benjamin Besse, David Planchard, et al.
Therapeutic Advances in Respiratory Disease|November 6, 2019
Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experienceAngela Botticella, Laura Mezquita, Cecile Le Pechoux, et al.
Lung Cancer (Amsterdam, Netherlands)|December 23, 2021
Antibody-drug conjugates: A promising novel therapeutic approach in lung cancerAakash Desai, Pamela Abdayem, Alex A Adjei, et al.
Bulletin Du Cancer|April 5, 2011
[DNA repair pathways and non-small cell lung cancer: clinical perspectives]Ken André Olaussen, David Planchard, Julien Adam, et al.
Seminars in Oncology|December 10, 2009
Differential expression of biomarkers in men and womenDavid Planchard, Yohann Loriot, Aicha Goubar, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 23, 2015
A Long-Term Spinal Intramedullary Response to Ceritinib in ALK Rearranged Non-Small-Cell Lung CancerJosette Biya, Caroline Caramella, Colin R Lindsay, et al.
Critical Reviews in Oncology/Hematology|May 5, 2025
Evolving treatment for advanced non-small cell lung cancer harbouring common EGFR activating mutationsIgor Gomez-Randulfe, Federico Monaca, David Planchard, et al.
Bulletin Du Cancer|March 31, 2015
[Second generation ALK inhibitors in non-small cell lung cancer: systemic review]Marie Viala, Solenn Brosseau, David Planchard, et al.
Cancer|March 15, 2012
p38 Mitogen-activated protein kinase signaling, ERCC1 expression, and viability of lung cancer cells from never or light smoker patientsDavid Planchard, Valérie Camara-Clayette, Nicolas Dorvault, et al.
Future Oncology (London, England)|June 30, 2021
Biosimilars in an era of rising oncology treatment optionsMarc Peeters, David Planchard, Mark Pegram, et al.
Pageof 25